文献速递妇科

新加坡学龄期九价人乳头瘤病毒疫苗对女性的临床与经济影响:一项传播动态数学模型分析

Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
PubMed 文献 · BJOG · 2018-01-01

本研究采用传播动态数学模型,基于新加坡临床、流行病学和财务数据,分析11至12岁女孩学校基础两剂九价HPV疫苗接种对比二价和四价疫苗的流行病学与经济影响。结果显示九价疫苗额外降低HPV31/33/45/52/58相关CIN1 40.5%、CIN2/3 35.4%、宫颈癌23.5%和宫颈癌死亡20.2%,并具有成本效果。

要点

  • 九价HPV疫苗较二价和四价额外降低HPV31/33/45/52/58相关CIN1 40.5%、CIN2/3 35.4%、宫颈癌23.5%、宫颈癌死亡20.2%。
  • 较二价疫苗,九价额外降低HPV6/11相关CIN1 75.7%、女性生殖器疣78.9%、男性生殖器疣73.4%。
  • 100年内经3%贴现,疾病管理成本较二价降低32.5%、较四价降低7.5%;每获得质量调整生命年ICER分别为929和9864新加坡元。

核心结论

  • 对11至12岁青少年女性普遍接种两剂九价HPV疫苗在新加坡极具成本效果。

研究设计与样本

  • 研究设计为数学模型,采用经校验的HPV传播动态数学模型进行药物经济学模拟预测,人群为新加坡人口。

主要发现

  • 较二价和四价HPV疫苗接种规划,九价普遍接种额外降低HPV31/33/45/52/58相关CIN1 40.5%、CIN2/3 35.4%、宫颈癌23.5%、宫颈癌死亡20.2%。
  • 较二价HPV疫苗,额外降低HPV6/11相关CIN1 75.7%、女性生殖器疣78.9%、男性生殖器疣73.4%。
  • 100年内经3%贴现,疾病管理成本较二价降低32.5%、较四价降低7.5%。
  • 每获得质量调整生命年的增量成本效果比(ICER)较二价疫苗为929新加坡元、较四价疫苗为9864新加坡元。

关键数值与推荐

  • 模型假设常规细胞学筛查维持当前50%的覆盖率,疫苗覆盖率为80%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the epidemiological and economic impact of a nine-valent (nonavalent) human papillomavirus (HPV) 6/11/16/18/31/33/45/52/58 vaccine programme for young teenagers in Singapore. DESIGN: Mathematical modelling. SETTING: Pharmaco-economic simulation projection. POPULATION: Singapore demography. METHODS: Clinical, epidemiological and financial data from Singapore were used in a validated HPV transmission dynamic mathematical model to analyse the impact of nonavalent HPV vaccination over quadrivalent and bivalent vaccines in a school-based 2-dose vaccination for 11- to 12-year-old girls in the country. The model assumed routine cytology screening in the current rate (50%) and vaccine coverage rate of 80%. MAIN OUTCOME MEASURES: Changes over a 100-year time period in the incidence and mortality rates of cervical cancer, case load of genital warts, and incremental cost-effectiveness ratio (ICER). RESULTS: Compared with bivalent and quadrivalent HPV vaccination programmes, nonavalent HPV universal vaccination resulted in an additional reduction of HPV31/33/45/52/58 related CIN1 of 40.5%, CIN 2/3 of 35.4%, cervical cancer of 23.5%, and cervical cancer mortality of 20.2%. Compared with bivalent HPV vaccination, there was an additional reduction in HPV-6/11 related CIN1 of 75.7%, and genital warts of 78.9% in women and 73.4% in men. Over the 100 years, after applying a discount of 3%, disease management cost will be reduced by 32.5% (versus bivalent) and 7.5% (versus quadrivalent). The incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year gained was SGD 929 compared with bivalent vaccination and SGD 9864 compared with quadrivalent vaccination. CONCLUSION: Universal two-dose nonavalent HPV vaccination for 11- to 12-year-old adolescent women is very cost-effective in Singapore. TWEETABLE ABSTRACT: Nonavalent HPV vaccination of 11- to 12-year-old girls is cost-effective in Singapore.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Tay SK, Hsu TY, Pavelyev A, et al. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis. BJOG. 2018. PMID: 29266694. doi:10.1111/1471-0528.15106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。